The company no longer plans to develop cell-free DNA assays for oncology but will instead look to commercialize a new target capture technology.
The Pro-Seq technology links molecules prior to sequencing to enable detection of low-frequency variants, and could be complementary to Boreal's OnTarget technology.
Trovagene, Boreal Genomics to Co-Develop Kits for ctDNA Analysis
The companies will co-develop kits, which Trovagene will distribute globally, to analyze ctDNA from blood or urine using next-generation sequencing platforms.
Boreal to Offer OnTarget Tumor Mutation Detection Through Clinical Partnerships; Broaden Assay
Over the last two years, the Vancouver, British Columbia-based company has been offering the assay as a service to academic and pharmaceutical researchers.
Cancer Genomics Firm Boreal Genomics Raises $18M
NEW YORK (GenomeWeb News) – Boreal Genomics said today that it has completed an $18 million Series C financing round, which will be used to expand its commercial operations and launch clinical applications.
Mar 20, 2013
Apr 17, 2012
Feb 22, 2012
Feb 21, 2012
Feb 16, 2012
Jul 6, 2011
Pairings: Jul 6, 2011
Jul 5, 2011
Paired Ends: Jul 5, 2011
Jun 30, 2011
People in the News: Jun 30, 2011
Dec 16, 2010
Dec 15, 2010
Boreal Genomics Raises $6.9M in Private Financing
May 13, 2010